anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study aim is to perform MR Spectroscopy (1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI on 115 patients with biopsy proven adenocarcinoma of the breast, who will be receiving neoadjuvant chemotherapy as per standard therapeutic protocol, prior to surgical management. The spectroscopic data will be analyzed to determine whether this can enable early prediction of therapeutic response as assessed by RECIST and ultimately surgical pathology after the completion of the full course of drug treatment. The 1H MRS, which is performed at baseline, prior to treatment, halfway through and at the end of the chemotherapy course, just prior to surgery, will be added to the routine MRI examination for the affected breast. Since chemotherapy courses vary in length, the exact timeline will depend on the specific course given. 1H MRS will add 10 minutes to the routine MRI examination, but will not involve additional injections of contrast. In addition, we will perform two extra MRIs combined with 1H MRS examinations for the affected breast, one set the day after and the second set one week after the initiation of chemotherapy. The MRI and 1H MRS will be performed at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY, NY 10021 or at any offsite of MSKCC.
PURPOSE:To reduce fatigue associated with operation of a medical picture processor and, at the same time, to easily confirm picture to be transferred by moving a cursor mark on a displaying section after the mark is displayed and displaying the medical picture information corresponding to the retrieval information coincided with the cursor mark. CONSTITUTION:After medical picture information is displayed on a displaying section 3, an operator moves a cursor mark 10 so as to coincide with a directory 9 by using a mouse 4 and depresses a push button. Then a picture selecting means 15 finds the file name if medical picture information stored in a storing section 1 from the coordinate values of the cursor mark 10 and transmits the file name to a picture data loading means 11. When the operator depresses another push button, the means 11 reads out the medical picture information corresponding to the file name from the storing section 1 and writes the picture data in the storing area of a frame memory 6 through picture data compressing means 12, temporary picture storing means 13, and window converting and picture displaying means 14. The written picture data are displayed on the display section 3. Therefore, the fatigue associated with the operation of the device can be reduced and transferred pictures can be confirmed easily.
Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
A randomized open-label, multicenter, controlled trial evaluated 170 adult patients with myelodysplastic syndromes (MDS) meeting French-American-British (FAB) classification criteria and International Prognostic Scoring System (IPSS) High-Risk, Intermediate-2 and Intermediate-1 prognostic scores. Eighty-nine patients were randomized to decitabine for injection therapy plus supportive care (only 83 received decitabine for injection), and 81 to Supportive Care (SC) alone. Patients with Acute Myeloid Leukemia (AML) were not intended to be included. Of the 170 patients included in the study, independent review (adjudicated diagnosis) found that 12 patients (9 in the decitabine for injection arm and 3 in the SC arm) had the diagnosis of AML at baseline. Baseline demographics and other patient characteristics in the Intent-to -Treat (ITT) population were similar between the 2 groups, as shown in Table 4.

Patients randomized to the decitabine for injection arm received decitabine for injection intravenously infused at a dose of 15 mg/m2 over a 3-hour period, every 8 hours, for 3 consecutive days. This cycle was repeated every 6 weeks, depending on the patient's clinical response and toxicity. Supportive care consisted of blood and blood product transfusions, prophylactic antibiotics, and hematopoietic growth factors. The study endpoints were overall response rate (complete response + partial response) and time to AML or death. Responses were classified using the MDS International Working Group (IWG) criteria; patients were required to be RBC and platelet transfusion independent during the time of response. Response criteria are given in Table 5:

The overall response rate (CR+PR) in the ITT population was 17% in decitabine for injection - treated patients and 0% in the SC group (p<0.001). (See Table 6) The overall response rate was 21% (12/56) in decitabine for injection - treated patients considered evaluable for response (i.e., those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment). The median duration of response (range) for patients who responded to decitabine for injection was 288 days (116 to 388) and median time to response (range) was 93 days (55 to 272). All but one of the decitabine for injection-treated patients who responded did so by the fourth cycle. Benefit was seen in an additional 13% of decitabine for injection-treated patients who had hematologic improvement, defined as a response less than PR lasting at least 8 weeks, compared to 7% of SC patients. Decitabine for injection treatment did not significantly delay the median time to AML or death versus supportive care.

All patients with a CR or PR were RBC and platelet transfusion independent in the absence of growth factors.

Responses occurred in patients with an adjudicated baseline diagnosis of AML.
FIELD: biology, peptides. SUBSTANCE: method involves brain tissue homogenization, acid extraction, precipitate separation and isolation of lyophilized preparation. Pineal gland tissue is extracted twice with 0.1-1.0 N perchloric acid aqueous solution at 2-6 C for 12-48 h. Extract is neutralized with potassium hydroxide aqueous solution followed by potassium perchlorate separation, purification and the preparation isolation by heating and double lyophilization of the neutralized extract. Preparation can be used in pharmacy, agriculture, medicine and veterinary science. EFFECT: improved method of preparing. 3 dwg, 1 tbl
PURPOSE: To obtain a dispersible solid medicinal preparation containing finely divided diclofenac as a free acid. CONSTITUTION: This dispersible preparation, which contains finely divided powdery diclofenac about 4-100μm in particle size, is obtained by formulating the above active ingredient with 5-25wt.% of a disintegrant (e.g. fine crystalline cellulose), diluent (e.g. lactose) and, if needed, up to 0.1wt.% of moisturizing agent and/or up to 2wt.% of lubricant, and also colorant, flavoring agent, aromatic agent, pref. into tablet form. The diclofenac is an effective analgesic plus antiarrhythmic agent; by dispersing the diclofenac as a free acid rather than a salt, this medicinal preparation is made easy to take without experiencing any bitter taste.
PROBLEM TO BE SOLVED: To prepare an antimicrobial agent for an oral cavity, comprising a γ-lactone having a specific number of carbon atoms as an active ingredient and having excellent antimicrobial activities against periodontosis, halitosis, subgingival dental plaque and dental caries causative bacteria and high safety. SOLUTION: This antimicrobial agent for an oral cavity is obtained by using an 11-16C γ-lactone as an active ingredient. For example, γ-undecalactone, γ- dodecalactone and γ-tridecalactone, γ-tetradecalactone are cited as the 11-16C γ-lactone. When the antimicrobial agent for the oral cavity is used as a composition for the oral cavity, the amount thereof blended is preferably 0.0001-5wt.%, especially preferably 0.001-3wt.% based on the whole composition for the oral cavity. The antimicrobial agent for the oral cavity may be used alone or in a mixture of two or more thereof in combination. Stronger antimicrobial activities can be manifested by using them with an existing antimicrobial perfume or a synthetic antimicrobial agent at a concentration without causing problems in safety.
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Participants received albumin-bound paclitaxel 100 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
Atrial fibrillation (AF) is the most common sustained arrhythmia in humans, yet the molecular basis of AF remains incompletely understood. To determine the cell type-specific transcriptional changes underlying AF, we perform single-nucleus RNA-seq (snRNA-seq) on left atrial (LA) samples from patients with AF and controls. From more than 175,000 nuclei we find that only cardiomyocytes (CMs) and macrophages (MΦs) have a significant number of differentially expressed genes in patients with AF. Attractin Like 1 (ATRNL1) was overexpressed in CMs among patients with AF and localized to the intercalated disks. Further, in both knockdown and overexpression experiments we identify a potent role for ATRNL1 in cell stress response, and in the modulation of the cardiac action potential. Finally, we detect an unexpected expression pattern for a leading AF candidate gene, KCNN3. In sum, we uncover a role for ATRNL1 which may serve as potential therapeutic target for this common arrhythmia.
1460915 D-(-)-2-(p-Hydroxyphenyl)glycyl chloride hydrochloride BRISTOL-MYERS CO 21 Dec 1973 [26 Dec 1972] 39618/74 Divided out of 1460914 Heading C2C D - (-) - 2 - (p - hydroxyphenyl)glycol chloride hydrochloride having the formula is prepared by reacting D-(-)-2-(p-hydroxyphenyl)glycine with a molar excess of phosgene in an anhydrous inert solvent as defined hereinafter, to form a solution of the anhydride of formula removing unreacted phosgene from the reaction mixture, adding a stoichiometric excess of HCl gas to the cooled reaction mixture, and recovering the desired product. The reaction solvent is a liquid which is chemically inert to the reactants and product, is a solvent for the intermediate anhydride, and is substantially non-solvent for the desired end product, suitable solvents being dioxane, tetrahydrofuran and acetonitrile. Further non-solvents, e.g. chlorinated hydrocarbons and aromatic hydrocarbons may be added at the final stage to encourage precipitation of the product. The product may be obtained in the form of a solvate with the reaction solvent (e.g. the dioxane or acetonitrile solvate), and this may be converted to the non-solvated form by gassing in solution or suspension with further HCl gas or by slurrying with anhydrous methylene chloride.
Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) \>5 events/hour and \<10 events/hour with Epworth Sleepiness Score (ESS)\>9.
The invention relates to a drug for treatment of primary dysmenorrheal. The drug is prepared from the following raw herbal materials by weight: 6 parts of cinnamon, 6 parts of rhizoma cyperi preparata, 8 parts of Ligusticum wallichii, and 9 parts of corydalis tuber. According to the treatment experience of family academic context, by understanding the main idea of ancient books and combining the pathological study of modern medicine on gynecological diseases, the inventor summarizes the drug for treatment of primary dysmenorrheal. In the formula, the cinnamon is pungent and sweet, has great heat, is distributed to kidney, spleen, heart and liver channels, can tonify fire and reinforce yang, conduct fire to its origin, dispel cold to relieve pain, and activate blood and dredge meridians; the rhizoma cyperi acts on liver, spleen and triple energizer meridian, and has the efficacy of regulating qi and relieving stagnancy, regulating menstruation and relieving pain; and the Ligusticum wallichii can promote blood and qi circulation, dispel wind and relieve pain, and can be used for irregular menstruation, amenorrhea and dysmenorrheal; and the corydalis tuber can regulate menstruation and relieve pain. All the Chinese herbs are used in combination to treat primary dysmenorrheal, and basically can vanish the symptoms when the drug takes effect. Clinical trials prompt that the drug provided by the invention can be safely and effectively applied to treatment of primary dysmenorrhea.
Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
Osteoarthritis (OA) is characterized by cartilage damage, inflammation, and pain. Vascular endothelial growth factor receptors (VEGFRs) have been associated with OA severity, suggesting that inhibitors targeting these receptors alleviate pain (via VEGFR1) or cartilage degeneration (via VEGFR2). We have developed a nanoparticle-based formulation of pazopanib (Votrient), an FDA-approved anticancer drug that targets both VEGFR1 and VEGFR2 (Nano-PAZII). We demonstrate that a single intraarticular injection of Nano-PAZII can effectively reduce joint pain for a prolonged time without substantial side effects in two different preclinical OA rodent models involving either surgical (upon partial medial meniscectomy) or nonsurgical induction (with monoiodoacetate). The injection of Nano-PAZII blocks VEGFR1 and relieves OA pain by suppressing sensory neuronal ingrowth into the knee synovium and neuronal plasticity in the dorsal root ganglia and spinal cord. Simultaneously, the inhibition of VEGFR2 reduces cartilage degeneration. These findings provide a mechanism-based disease-modifying drug strategy that addresses both pain symptoms and cartilage loss in OA.
Prodn. of homeopathic medicines effected by dissolving a C3 triturate of the active substance in dil. EtOH, dissolving one drop of the soln. in 2.5 ml of 86% EtOH, shaking the soln. 100 times, wetting a few grams of size-I sugar granules with the soln., and air drying the wetted granules in a closed vessel.  Pref. 60 mg. of the C3 triturate is dissolved in 20 ml of 15% EtOH, and 2 g of the sugar granules are used, giving a MI potency.  A higher potency (MII) may be obtained by dissolving 1 or 2 of the granules in one drop of water, adding 2.5 ml of 86% EtOH,  shaking 100 times, and mixing 0.1 g of the soln. with 25 g of 48% EtOH. ADVANTAGE - Homeopathic medicines are produced in high potencies.
NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
In the process of murder investigation, it is of great significance to find the discarded and buried human remains accurately. The main methods of searching for human remains include human visual search, aerial detection, geophysical technology, remote imaging technology and canine olfactory search technique. Canine olfactory search for human remains is a recognized time-effective and non-invasive search method, making dogs the most valuable search tool in forensic investigation. By systematically reviewing and summarizing relevant literature, and based on the theory of volatile organic compound produced by the decomposition of human remains, this paper explores the basic principle of the canine olfactory search technique for human remains. This paper also reviews the application of training canine search technique for human remains in forensic investigation by using human blood, tissue, cadaver putrefying fluid and odor substitutes as sniffing sources. The application prospect of canine olfactory search for human remains was prospected from the perspectives of detection of volatile organic compound during cadaver decay, development of odor substitutes and adsorption devices, and technology tactics used in canine training and use, to provide references for the relevant research of canine olfactory search for human remains in China.
Fosinopril sodium and hydrochlorothiazide tablets can cause symptomatic hypotension. Like other ACE inhibitors, fosinopril has been only rarely associated with hypotension in uncomplicated hypertensive patients. Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Volume and/or salt depletion should be corrected before initiating therapy with fosinopril sodium and hydrochlorothiazide tablets.

Fosinopril sodium and hydrochlorothiazide tablets should be used cautiously in patients receiving concomitant therapy with other antihypertensives. The thiazide component of fosinopril sodium and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. The antihypertensive effects of the thiazide component may also be enhanced in the postsympathectomy patient.

In patients with congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension, which may be associated with oliguria, azotemia, and (rarely) with acute renal failure and death. In such patients, fosinopril sodium and hydrochlorothiazide tablet therapy should be started under close medical supervision; they should be followed closely for the first 2weeks of treatment and whenever the dose of fosinopril or diuretic is increased.

If hypotension occurs, the patient should be placed in a supine position, and, if necessary, treated with intravenous infusion of physiological saline. Fosinopril sodium and hydrochlorothiazide tablet treatment usually can be continued following restoration of blood pressure and volume.
PURPOSE: An orchid Vanda coerulea extract as a cosmetic active agent is provided to control cell cycle in the skin and to reduce skin aging signal. CONSTITUTION: An orchid Vanda coerulea extract delays the expression of skin aging signal. The extract is applied to face or body skin which indicates skin thickness, dryness, and elasticity. The extract is isolated from stems, roots, and leaves of orchid Vanda coerulea using polar solvent. The polar solvent is water, C1-C4 alcohol, ethanol, C2-C6 glycol, glycerol, butylene glycol, propylene glycol, or mixture thereof. A composition contains 0.001-5 weight% of dried extract and other orchid extract.
Sepsis-induced tissue and organ damage is caused by an overactive inflammatory response, immune dysfunction, and coagulation dysfunction. Danger-associated molecular pattern (DAMP) molecules play a critical role in the excessive inflammation observed in sepsis. In our previous research, we identified NMI as a new type of DAMP molecule that promotes inflammation in sepsis by binding to toll-like receptor 4 (TLR4) on macrophage surfaces, activating the NF-κB pathway, and releasing pro-inflammatory cytokines. However, it is still unknown whether NMI plays a significant role in other pathways. Our analysis of bulk and single-cell transcriptome data from the GEO database revealed a significant increase in NMI expression in neutrophils and monocytes in sepsis patients. It is likely that NMI functions through multiple receptors in sepsis, including IFNAR1, IFNAR2, TNFR1, TLR3, TLR1, IL9R, IL10RB, and TLR4. Furthermore, the correlation between NMI expression and the activation of NF-κB, MAPK, and JAK pathways, as well as the up-regulation of their downstream pro-inflammatory factors, demonstrates that NMI may exacerbate the inflammatory response through these signaling pathways. Finally, we demonstrated that STAT1 phosphorylation was enhanced in RAW cells upon stimulation with NMI, supporting the activation of JAK signaling pathway by NMI. Collectively, these findings shed new light on the functional mechanism of NMI in sepsis.
To determine the prevalence of functional, respiratory and renal impairments and of post-intensive-care-syndrome (PICS) among patients who had attended a post-ICU multidisciplinary consultation (post-ICU-MC) around 3 months after ICU discharge, we performed a retrospective, monocentric observational study, at Clermont Ferrand University hospital, France. We included patients who had attended a post-ICU-MC. Their characteristics during ICU stay and at the post-ICU-MC were collected. Functional status was assessed by the 6-min-walking test, handgrip test and peak inspiratory pressure, respiratory function by exploratory functional outcomes, mental status by SF-36 score, and quality of life by SF-36 score and European Quality of Life 5 Dimensions questionnaire. Overall, we enrolled 67 patients, of whom 70%, 74%, and 68% had functional, respiratory, and renal impairments, respectively, at the post-ICU-MC. Additionally, 40%, 28%, 19%, and 2.5% had three, two, one, and none of these impairments, respectively. All patients experienced mental disorders and a decline in quality of life. Functional impairment correlated with frailty score and sex, and respiratory function with age. To conclude, the prevalence of PICS in our cohort was high, as was that of functional, respiratory and renal failure.
Immediately after the placenta was expelled, clamping with collum overpens and controlled traction visible through the vaginal introitus were applied to the women in the intervention group of the study. Traction was applied for 90 seconds.